Partnering Opportunity

Research Development Request

H2020-SC1-DTH-2018-2020: French SME offering 'eye-based analysis' solutions for early detection of Alzheimer / Dementia seeks clinical partnerships for assessment / validation of a new screening device.

Summary

A French SME has developed an innovative 'eye-tracking' medical device to help diagnosing neurological and psychiatric diseases by bringing up robust and quantitative oculomotor neuromarkers for early disease detection and follow-up. The company, after preliminary and promising results in Alzheimer's Disease (AD), is looking for partners to submit a proposal for H2020-SC1-DTH-2018-2020 call to finalize and validate the tool at a larger scale. Clinical partners and a coordinator are sought.

Creation Date	17 March 2020
Last Update	19 March 2020
Expiration Date	15 April 2020
Reference	RDFR20200317001
Public Link	https://een.ec.europa.eu/tools/services/PRO/Profile/Detail/7bfc8880-6a37-4aa8-8ff4-aa5ed81a6f1d

Details

Description

This French R&D company was founded in 2013 with the focus of developing an innovative embedded eyetracking technology dedicated to the diagnosis of neurological and psychiatric disorders.

Based on data resulting from a first step of development (50 medical research centers worldwide, 70 publications, 25 patents, reimbursement in France and Switzerland), the company focuses on the neurodegenerative diseases.

The device is an integrative platform for a quick, robust and reproducible clinical oculomotor examination of several conditions including AD, Multiple Sclerosis and Parkinson disease. A recent article demonstrated that recording oculomotor behavior with the device can be a powerful tool to identify attentional deficits in AD patients as well as in individuals at the prodromal stage (Mild Cognitive Impairment). Consequently, eye movements and pupil size based neuromarkers are highly valuable candidates to efficiently discriminate individuals at-risk of developing AD from healthy individuals.

The current challenge is then to unravel the most specific and sensitive oculomotor neuromarkers for diagnosis and monitoring AD. To do so, the French company is looking for partners to apply to the call: H2020-SC1-DTH-2018-2020.
Call deadline: April 22, 2020. It would be appreciated to receive the expressions of interest before April 15, 2020.

To build the most relevant consortium, clinical and medical partners to conduct clinical trials and to deal with cohort trials are sought. The French SME is also looking for a partner to coordinate the project.

Advantages and innovations

The company has built a robust software and hardware platform in the field of gaze tracking applied in the neuro-medical field.

Based on 25 patents, medical device CE certified (mandatory for diagnostic indication), reimbursed in some European countries, and already used in several continents. The device allows direct translational use for medical research to clinical routine. It includes all the necessary functionalities [data patient management, powerful automated analysis, medical reporting, norms, and a set of validated paradigms to explore executive and neurocognitive functions] to empower and facilitate the development and validation of a new screening tool in AD, as recent publications using the device show promising results in this indication.

Stage of development

Already on the market

Comments Regarding Stage of Development

The current aim is to finalize and validate the tool at a larger scale.

IPR Status

Patent(s) applied for but not yet granted,Patents granted

Keywords

Technology

06001005	Diagnostics, Diagnosis
06001012	Medical Research
06001014	Neurology, Brain Research
06005002	Sensors & Wireless products

06005003	Health information management

Market

05001001	Diagnostic services
05001003	Differential diagnosis
05004005	Diagnostic equipment

NACE

M.72.1.1	Research and experimental development on biotechnology
Q.86.2.2	Specialist medical practice activities

Network Contact

Issuing Partner

ZACHODNIOPOMORSKI UNIWERSYTET TECHNOLOGICZNY W SZCZECINIE

Contact Person

Zebrowski Pawel

Phone number

+48 91 449 43 64

Email

pzebrowski@zut.edu.pl

Open for EOI: Yes

Dissemination

Relevant sector groups

Healthcare

Client

Type and Size of Organisation Behind the Profile

Industry SME 11-49

Year Established

2013

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
French

Client Country

France

Partner Sought

Type and Role of Partner Sought

Two types of partners are sought:
- clinical / medical research organisations concerned by early Alzheimer detection / characterization (public, private), able or willing to conduct clinical / cohort trials in this field.
- a coordinator with experience in H2020 project coordination. It could be one of the clinical/medical partners or a company involved in this field.

Type and Size of Partner Sought

SME 11-50,University,R&D Institution,SME <10,SME 51-250

Type of Partnership Considered

Research cooperation agreement

Program - Call

Framework Program

H2020

Call title and identifier

Personalised early risk prediction, prevention and intervention based on Artificial Intelligence and Big Data technologies

Anticipated Project Budget

2 M€

Coordinator required

Yes

Acronym

Personalised early risk prediction, prevention in Alzheimer Disease

Duration

120 days

Deadline for EOI

15 Apr 2020

Deadline of the Call

22 Apr 2020

Weblink to the call

https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-dth-02-2020

Attachments